Ewing Sarcoma

Ewing sarcoma is a highly aggressive primary malignant bone tumor defined by a characteristic chromosomal translocation that creates an aberrant transcription factor. It is the second most common primary bone cancer in children and young adults, notorious for its inflammatory presentation that mimics infection, and requires intensive multimodal therapy combining chemotherapy with surgery or radiation to achieve cure.

Table of Contents

  1. Overview and Epidemiology
  2. Molecular Hallmark: EWSR1 Fusions
  3. Pathology and Immunohistochemistry
  4. Clinical Presentation
  5. Imaging and Staging
  6. Differential Diagnosis
  7. Multidisciplinary Treatment Approach
  8. Chemotherapy Protocols
  9. Local Control: Surgery vs Radiation
  10. Prognosis and Outcomes
  11. Key Research Papers
  12. PubMed Topic Searches
  13. Connections
  14. Featured Videos

Overview and Epidemiology

Ewing sarcoma is the second most common primary malignant bone tumor in children and adolescents, trailing only osteosarcoma. Approximately 200 new cases are diagnosed each year in the United States, making it a rare but important malignancy given its predilection for young patients and potentially curable nature. The disease belongs to a broader family known as the Ewing sarcoma family of tumors (ESFT), which encompasses a spectrum of related neoplasms united by shared molecular abnormalities.

Within the ESFT spectrum:

The peak incidence falls between ages 10 and 20 years, making Ewing sarcoma slightly younger at presentation than osteosarcoma. The disease is rare before age 5 and uncommon after age 30; cases in adults over 40 are exceptional and may carry a different prognosis. The male-to-female ratio is approximately 1.5:1.

One of the most striking epidemiological features of Ewing sarcoma is its racial distribution. The tumor occurs predominantly in individuals of White/European ancestry and is distinctly rare in people of African or Asian descent. This disparity is far more extreme than for most other cancers and strongly suggests a genetic predisposition linked to ancestry-specific germline variants rather than purely environmental exposures. The specific germline factors responsible have been a subject of active research, with GGAA microsatellite polymorphisms near ETS-family gene loci proposed as contributing elements.

The cell of origin of Ewing sarcoma remains an area of active debate. Early theories proposed neural crest derivation based on the partial neural differentiation seen in PNET variants. More recent data from gene expression profiling and epigenetic studies favor a mesenchymal stem cell origin, with the EWSR1-FLI1 fusion oncogene reprogramming the cell toward a dedifferentiated, highly proliferative state. The tumor retains plasticity, which may explain the variable histological features across ESFT subtypes.

Back to Table of Contents

Molecular Hallmark: EWSR1 Fusions

The defining molecular event in Ewing sarcoma is a chromosomal translocation that fuses the EWSR1 gene (Ewing sarcoma RNA-binding protein 1, chromosome 22q12) to a member of the ETS family of transcription factors. This fusion creates an aberrant chimeric transcription factor that drives widespread oncogenic reprogramming of the cell.

The translocation t(11;22)(q24;q12), producing the EWSR1-FLI1 fusion oncogene, is found in approximately 85% of all Ewing sarcoma cases. FLI1 (Friend Leukemia Integration 1) is an ETS-family transcription factor that normally regulates hematopoiesis and vascular development. When the N-terminal transactivation domain of EWSR1 replaces the normal regulatory domain of FLI1, the resulting fusion protein becomes a constitutively active, aberrant transcription factor capable of activating genes that are normally silenced and repressing genes that are normally expressed.

Additional EWSR1-ETS fusions account for the remaining cases:

Confirmation of an EWSR1 fusion is essential for diagnosis and is performed by fluorescence in situ hybridization (FISH) detecting EWSR1 rearrangement or by reverse-transcription PCR (RT-PCR) identifying the specific fusion transcript. FISH for EWSR1 break-apart is highly sensitive but does not identify the fusion partner; RT-PCR or RNA sequencing specifies the partner gene, which may have prognostic implications.

At the mechanistic level, EWSR1-FLI1 exerts its oncogenic effects through multiple pathways:

The GGAA microsatellite polymorphism hypothesis also provides a partial explanation for the racial disparity in Ewing sarcoma incidence: European-ancestry populations carry longer GGAA repeat lengths at specific loci, potentially creating more permissive binding sites for EWSR1-FLI1 if the translocation occurs in a susceptible progenitor cell.

Back to Table of Contents

Pathology and Immunohistochemistry

On light microscopy, Ewing sarcoma presents as a small round blue cell tumor — a morphological category that includes several highly aggressive neoplasms of childhood. The cells are undifferentiated and primitive, with:

PAS staining (periodic acid–Schiff) may reveal intracytoplasmic glycogen, which is diastase-sensitive — a classic but nonspecific finding. No osteoid production is present, which distinguishes Ewing sarcoma from osteosarcoma at the histological level even when the two tumors arise in adjacent sites.

In the PNET variant, cells cluster into Homer-Wright rosettes — circular arrangements of tumor cells around central neuropil fibrils — reflecting partial neural differentiation. True rosettes with central lumina (Flexner-Wintersteiner rosettes) are not a feature of Ewing sarcoma.

Immunohistochemistry (IHC) is essential for the diagnosis:

Molecular confirmation by FISH or RT-PCR for EWSR1 rearrangement is required in all cases — morphology and IHC alone are insufficient for definitive diagnosis of Ewing sarcoma given the significant differential of CD99-positive small round cell tumors.

Back to Table of Contents

Clinical Presentation

The clinical presentation of Ewing sarcoma is dominated by pain and swelling at the site of the primary tumor, often present for weeks to months before diagnosis. Because the tumor most commonly arises in the diaphysis (shaft) of long bones or in flat bones such as the pelvis and ribs — rather than near a joint — symptoms may be attributed to athletic injury, growing pains, or musculoskeletal strain, contributing to diagnostic delays.

Systemic inflammatory signs are a hallmark that distinguishes Ewing sarcoma from most other bone tumors and creates its reputation as the "great masquerader":

This combination of focal bone pain, fever, leukocytosis, and periosteal reaction on imaging closely mimics acute osteomyelitis. The median delay from symptom onset to diagnosis has been reported to exceed 6 months in some series, often after a period of empiric antibiotic treatment. Clinical suspicion must be maintained for any young patient with persistent bone pain and inflammatory markers that do not resolve with standard antibiotic therapy.

Site-specific presentations:

Metastatic disease at presentation is found in approximately 25% of patients. The most common metastatic sites are:

Pulmonary metastases may be bilateral and diffuse at presentation. Bone marrow involvement is detected by bilateral iliac crest trephine biopsies and is a staging requirement in all patients.

Back to Table of Contents

Imaging and Staging

Radiological evaluation of Ewing sarcoma begins with plain radiographs of the affected bone, which often reveal characteristic but nonspecific findings that prompt further cross-sectional imaging.

Plain radiograph findings:

MRI of the primary tumor is mandatory for surgical planning and provides:

Whole-body imaging for staging includes:

Staging in Ewing sarcoma follows a binary system: localized (no detectable distant metastases) vs metastatic (distant spread). This binary distinction is the primary prognostic determinant. Within localized disease, tumor volume and site (pelvic vs non-pelvic) are important secondary prognostic factors. There is no universally adopted AJCC-based staging system analogous to carcinomas.

Back to Table of Contents

Differential Diagnosis

The differential diagnosis of Ewing sarcoma is broad, encompassing both malignant tumors and infectious/inflammatory conditions. The "small round blue cell" histological appearance creates diagnostic overlap with several aggressive pediatric tumors.

Non-neoplastic conditions:

Other primary bone tumors:

Other small round blue cell tumors:

The diagnostic algorithm for any small round blue cell tumor requires integration of clinical history, imaging, IHC panel, and molecular studies. A diagnosis of Ewing sarcoma should never be made on morphology alone.

Back to Table of Contents

Multidisciplinary Treatment Approach

Ewing sarcoma is treated at specialized sarcoma centers where medical oncology, orthopedic oncology surgery, radiation oncology, radiology, and pathology collaborate in a multidisciplinary tumor board. The treatment framework applies to both localized and metastatic disease, though intensity and goals differ.

Diagnostic biopsy must be performed before any definitive treatment. Core needle biopsy under image guidance is preferred at experienced centers; open incisional biopsy is reserved for cases where core biopsy is nondiagnostic. The biopsy tract must be oriented so that it can be completely excised at the time of definitive surgical resection — a misplaced biopsy tract that contaminates the neurovascular bundle or an unresectable compartment is a serious surgical complication. Biopsy should be performed at the institution that will perform the definitive surgery whenever possible.

Treatment sequence:

  1. Induction systemic chemotherapy — 4–6 cycles (approximately 3–4 months) of full-dose multiagent chemotherapy before local control. This achieves rapid tumor volume reduction, treats micrometastatic disease, and allows interval assessment of chemotherapy sensitivity by histological evaluation of necrosis in the resected specimen.
  2. Local control — surgery, radiation therapy, or combined modality, timing approximately 3–4 months into treatment
  3. Consolidation chemotherapy — continuation of systemic chemotherapy after local control to complete the planned 12–17 cycle course

The Children's Oncology Group (COG) and the European Ewing Tumor Working Initiative of National Groups (Euro-E.W.I.N.G.) have conducted the pivotal randomized trials that define current standard of care. International collaboration is important given the rarity of the disease.

Metastatic disease is treated with the same backbone chemotherapy regimen, with local control applied to the primary site in most cases. The role of consolidation with high-dose chemotherapy and autologous stem cell rescue for metastatic disease remains controversial and is investigated within clinical trials. Bilateral pulmonary irradiation (12–15 Gy) is used at some centers for pulmonary-only metastatic disease, though evidence from prospective trials is limited.

Back to Table of Contents

Chemotherapy Protocols

The standard chemotherapy backbone for Ewing sarcoma in North America is VDC/IE: alternating cycles of Vincristine + Doxorubicin + Cyclophosphamide (VDC) with Ifosfamide + Etoposide (IE). In Europe, the standard five-drug regimen (VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide, for induction) followed by consolidation with VAC (Vincristine, Actinomycin-D, Cyclophosphamide) or VAI (Vincristine, Actinomycin-D, Ifosfamide) represents an alternative approach.

VDC/IE regimen details:

The landmark AEWS0031 trial (Children's Oncology Group, 2012) established that interval-compressed chemotherapy — administering VDC/IE cycles every 2 weeks instead of the standard 3-week interval, with G-CSF support — significantly improved outcomes:

This study changed practice in North America; the 2-week compressed schedule is now the standard of care for localized Ewing sarcoma in pediatric and adolescent patients.

Historical context: The INT-0091 trial (Grier et al., 2003) established the value of adding ifosfamide and etoposide to the standard vincristine-doxorubicin-cyclophosphamide backbone. Prior to this, 5-year EFS for localized disease with three-drug therapy was approximately 54%; addition of ifosfamide and etoposide improved EFS to approximately 69%, establishing VDC/IE as the new standard.

Toxicities of VDC/IE require proactive management:

Back to Table of Contents

Local Control: Surgery vs Radiation

The choice between surgery, radiation therapy, or combined modality for local control of Ewing sarcoma is one of the most complex decisions in the multidisciplinary management of this disease. The goal is durable local control with acceptable functional outcome and minimization of long-term toxicity. Decisions are made after induction chemotherapy, when the tumor has (ideally) shrunk and the feasibility of complete surgical resection can be reassessed.

Surgery is preferred when complete resection with adequate margins (R0 resection) is achievable without unacceptable functional loss. Key advantages of surgery include:

Limb-salvage surgery options include:

Amputation is reserved for cases where limb-salvage is technically impossible or where limb preservation would result in a functionless extremity. Rates of amputation have declined substantially at specialized sarcoma centers.

Radiation therapy (45–55 Gy in 1.8 Gy daily fractions) is used in the following situations:

Pelvic Ewing sarcoma presents the greatest local control challenge. The pelvis is the most common single primary site in adolescents and adults (25% of cases), and complete surgical resection often requires internal or external hemipelvectomy with significant morbidity. Definitive radiation is frequently employed, though local failure rates after radiation alone for large pelvic tumors remain higher than for extremity tumors treated with surgery.

Late effects of radiation in Ewing sarcoma are important considerations in patients who are often treated in childhood:

Back to Table of Contents

Prognosis and Outcomes

The prognosis for Ewing sarcoma is determined primarily by the extent of disease at diagnosis, tumor site and volume, and histological response to induction chemotherapy. With modern multimodal therapy, outcomes have improved substantially since the era of surgery alone or single-agent chemotherapy.

Localized disease:

Metastatic disease:

Key prognostic factors:

Relapsed disease carries a very poor prognosis regardless of prior therapy. Second-line agents with activity include gemcitabine + docetaxel, irinotecan + temozolomide, and high-dose chemotherapy with stem cell rescue. Median overall survival after first relapse is approximately 10–15 months. Novel targeted approaches — including EZH2 inhibitors (targeting the epigenetic dependence of EWSR1-FLI1–driven tumors), CDK inhibitors, and anti-IGF1R antibodies — have been evaluated in clinical trials with modest results. Immunotherapy with checkpoint inhibitors has shown limited single-agent activity to date in this tumor type.

Back to Table of Contents

Key Research Papers

  1. Grier HE et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348:694–701. PMID 12684360
  2. Womer RB et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012; 30:4148–4154. PMID 22869879
  3. Delattre O et al. The Ewing family of tumors — a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331:294–299. PMID 7969281
  4. Tirode F et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov 2014; 4:1342–1353. PMID 25010205
  5. Paulussen M et al. Ewing tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 1998; 16:3044–3052. PMID 9626215
  6. Bernstein M et al. Ewing's sarcoma family of tumors: current management. Oncologist 2006; 11:503–519. PMID 16794246
  7. Ladanyi M, Gerald W. Fusion of the EWS and FLI-1 genes in Ewing's sarcoma. Cancer Res 1994; 54:2837–2840. PMID 8187121
  8. Le Deley MC et al. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol 2014; 32:2440–2448. PMID 24493721
  9. Nesbit ME et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: an Intergroup Study. J Clin Oncol 1990; 8:1664–1674. PMID 2154441
  10. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol 2010; 11:184–192. PMID 20350161
  11. Granowetter L et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol 2009; 27:2536–2541. PMID 19255327
  12. Cotterill SJ et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18:3108–3114. PMID 10623712

Back to Table of Contents

PubMed Topic Searches

The following PubMed searches retrieve current primary literature on Ewing sarcoma:

  1. Ewing sarcoma EWSR1 FLI1 fusion translocation
  2. Ewing sarcoma chemotherapy VDC IE treatment
  3. Ewing sarcoma pelvis surgery radiation local control
  4. Ewing sarcoma metastasis prognosis outcomes

Back to Table of Contents

Connections

Back to Table of Contents